Biomarin Pharmaceutical layoffs, on the record
Every job cut, severance charge and restructuring Biomarin Pharmaceutical reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from 3,401 to 3,221.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | 3,401 | December 31, 2023 |
| 10-K for 2024 | 3,040 | December 31, 2024 |
| 10-K for 2025 | 3,221 | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryBioMarin announced a plan on October 6, 2022 to simplify its organizational design, including a planned reduction in headcount, and recorded related severance and termination costs.
Word for word“On October 6, 2022, the Company announced a plan to simplify its organizational design, which included a planned reduction in headcount.” 10-K for 2023
Our summaryCommitted to a workforce reduction of about 170 employees in the second quarter of 2024 as part of a restructuring tied to discontinuing some R&D programs and organizational redesign.
Word for word“During 2024, in connection with the discontinuation of certain research and development programs and organizational redesign efforts centered around the Company's strategic priorities, including the acceleration and maximization of VOXZOGO, establishing the ROCTAVIAN opportunity, focusing R&D activities on the assets that management believes will be the most productive and accelerate earnings per share through expanding margins, the Company committed to plans in the second and third quarters of 2024, to reduce its global workforce by approximately 170 and 225 employees, respectively.” 10-K for 2024
Our summaryCommitted to a second workforce reduction of about 225 employees in the third quarter of 2024 as part of the same restructuring, substantially completed by year end.
Word for word“These workforce reductions were substantially completed by the end of 2024.” 10-K for 2024
Our summaryRecorded total 2024 restructuring expenses, mostly severance and one-time employee benefits, impairments and other costs, included in SG&A.
Word for word“The restructuring charges and adjustments were included in SG&A in the Consolidated Statements of Income.” 10-K for 2024
Our summaryRecorded severance and restructuring costs in G&A expense tied to the portfolio strategy review and organizational redesign announced in 2024.
Word for word“The increase in G&A expense for 2024 compared to 2023 was primarily due to severance and restructuring costs associated with our portfolio strategy review and the associated organizational redesign efforts announced in 2024, and increased bad debt expense during the fourth quarter of 2024.” 10-K for 2024
Our summaryThe company decided to voluntarily withdraw ROCTAVIAN from the market because commercial opportunities were lower than expected, and recorded restructuring charges for inventory, asset impairments, severance and other costs.
Word for word“On December 17, 2025, we committed to a plan to voluntarily withdraw ROCTAVIAN from the market due to lower than previously anticipated commercial opportunities.” 10-K for 2025
Our summaryThe company recorded about $240 million of restructuring charges in 2025 for the ROCTAVIAN withdrawal, made up of an inventory write-off, asset impairment, severance and other costs.
Word for word“In connection with this strategic decision, we recorded approximately $240.0 million of restructuring charges in 2025 comprised of an inventory write-off, impairment of long-lived assets, severance and other costs.” 10-K for 2025
Biomarin Pharmaceutical filed 3 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Biomarin Pharmaceutical’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.